Outcome, Cost and Quality of life for chronic hepatitis C patients treated by peginterferon and ribavirin
| Autor: | Ming-Kun Ku, 古明崑 |
|---|---|
| Rok vydání: | 2010 |
| Druh dokumentu: | 學位論文 ; thesis |
| Popis: | 98 Background：3% of world’s population infected with hepatitis C virus( HCV ), 85﹪ of whom developed chronic hepatitis and 20-30﹪of these patients will progress to cir-rhosis within 10-20 years after infection. Thereafter, 1-4﹪of the patients with cirrhosis will eventually develop hepatocellular carcinoma each year. The current standard of most effective therapy is a combination of peginterferon weekly and ribavirin. Treat-ment duration of genotype-1 48 weeks and non-genotype-I 24 weeks, which success rate was more than 60-80%. Only eradication of HCV could prevent development of liver cirrhosis and hepatocellular carcinoma. Objective：To assess combination therapy in local teaching hospital about 1.success rates and related factors of combination therapy 2.changes of biochemistry and viral load during treatment course of combination therapy 3.adverse effect and safety of combination therapy 4.health care urilization of combination therapy 5.changes of quality of life during combination therapy course. Methods： This study included 2 parts. Part 1 was a retrospective cohort study. Patients received combination therapy of peginterferon and ribavirin in FooYin teaching hospi-tal between January 2004 and April 2009 were enrolled. Treatment duration of geno-type-1 was 48 weeks but genotype-1 with RVR and non-genotype-I was 24 weeks. We compared the differences of patients.s characteristics, treatment success rates, changes of biochemistry and viral load during treatment course, adverse effect, health care urilization and expendicture between treatment successor and failurer. Part 2 was a prospective cohort study. Patients received combination therapy after November 2009 were enrolled. We analyzed changes of quality of life during combination therapy course of patients. Results：78 patients were enrolled in part-1 study. 54 patients (69.2%) were treatment successor. 27 patients were genotype-1 and 27 patients were genotype-2. There were no differences of patients.s characteristics, changes of biochemistry during treatment, genotype and adverse effect between treatment successor and failure. Treatment suc-cess predictors were low pretreatment viral load |
| Databáze: | Networked Digital Library of Theses & Dissertations |
| Externí odkaz: |
|